Last reviewed · How we verify
Placebo via ELLIPTA inhaler
Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials.
Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials. Used for Clinical trial control / comparator (not a therapeutic indication).
At a glance
| Generic name | Placebo via ELLIPTA inhaler |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo is a non-therapeutic agent administered in the same formulation and route as an active drug to serve as a control comparator in randomized controlled trials. Any observed effects are attributable to the placebo effect—psychological and contextual factors rather than direct pharmacological action. The ELLIPTA inhaler is the delivery device; the contents are inert powder.
Approved indications
- Clinical trial control / comparator (not a therapeutic indication)
Common side effects
Key clinical trials
- Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators (PHASE4)
- A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation (PHASE2)
- A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
- Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) (PHASE2)
- An Open-label Study to Evaluate Correct Use and Ease of Use of the ELLIPTA DPI in Pediatric Subjects With Asthma (PHASE4)
- Effect of Fluticasone Furoate/Vilanterol on EIA in Adolescents (PHASE4)
- Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma (PHASE2)
- A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo via ELLIPTA inhaler CI brief — competitive landscape report
- Placebo via ELLIPTA inhaler updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI